Log In
Print this Print this

ondansetron (EUR-1025)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionOnce-daily oral formulation of ondansetron
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEmesis
Indication DetailsTreat chemotherapy-induced nausea and vomiting (CINV); Treat emesis; Treat post-operative nausea and vomiting (PONV)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today